As of November 15, 2026, Arvinas, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 12, 2026 to June 22, 2026, naming 1 appointment and 2 departures. The latest filing names Noah Berkowitz, leaving (Form 8-K, June 22, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Arvinas, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Arvinas, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-12 to 2026-06-22. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Arvinas, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2025-05-01 (layoff filings and notices).
Also on the record for Arvinas, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by D. E. Shaw & Co., L.P. | 5.4% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 6.12% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by D. E. Shaw & Co., L.P. | 5.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Kenneth Griffin | 0.4% of the class | 5%+ stakes | Source |
| October 15, 2025 | Stake report, Schedule 13D/A, by Logos Global Management LP | 3.4% of the class | 5%+ stakes | Source |
| August 22, 2025 | Stake report, Schedule 13D/A, by Logos Global Management LP | 8.6% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 1.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Arvinas, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Arvinas, Inc. and the records around it.
Arvinas, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- D. E. Shaw & Co., L.P. also filed stake reports on 29 other companies: American Eagle Outfitters, Inc. (Nov 2026), Gossamer Bio, Inc. (Oct 2026), Sweetgreen, Inc. (Oct 2026)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
Watch Arvinas, Inc.
Get an email when Arvinas, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arvinas, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Arvinas, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arvinas, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-22 | Out | 2026-07-03 | 8-K, 2026-06-22 | ||
| 2026-02-12 | Out | Director | 2026-02-12 | 8-K, 2026-02-12 | |
| 2026-02-12 | In | Director | 8-K, 2026-02-12 |
Why did they leave? What the filings say
For 1 of the 2 named departures below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Noah Berkowitz (filed 2026-06-22):
The Company expects that Dr. Berkowitz will remain as chief medical officer of the Company through July 3, 2026 before leaving to pursue other opportunities.
- John Houston, Director (filed 2026-02-12): the filing states no reason.
Who leads Arvinas, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John Houston, departure reported, effective 2026-02-12 (filed 2026-02-12). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Arvinas, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Arvinas, Inc., with the record behind each one.
Find candidates like Director at Arvinas, Inc.Every change, in the filing's words
Departing: Noah Berkowitz, effective 2026-07-03
On June 22, 2026, Arvinas, Inc., a Delaware corporation (the "Company"), and Noah Berkowitz, M.D., Ph.D., the Company's chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the "Departure").
- The Company has begun a search to find a new chief medical officer to replace Dr. Berkowitz.
- In connection with his Departure, on June 22, 2026, the Company and Dr. Berkowitz entered into a separation agreement and release of claims (the "Separation Agreement"), which includes a release of claims by Dr. Berkowitz in the Company's favor, Dr. Berkowitz's agreement to continued compliance with the terms of his proprietary information and assignment agreement, as well as confidentiality, cooperation and non-disparagement obligations.
- All other RSUs awards not accelerated shall be forfeited in accordance with the terms of the applicable RSU award.
- The acceleration of vesting is subject to taxation and applicable withholdings.
Departing: John Houston, Director, effective 2026-02-12
Change in President, Chief Executive Officer and Chair of the Board of Directors On February 10, 2026, John Houston, Ph.D., notified Arvinas, Inc. (the "Company") of his decision to resign as president, chief executive officer ("CEO") and chairperson of the Company's board of directors (the "Board"), effective February 12, 2026 (the "Effective Date").
Appointed: Randy Teel, Director
On February 11, 2026, the Board appointed Randy Teel, Ph.D., as the Company's president, CEO, and principal executive officer, and a member of the Board, effective as of the Effective Date.
- Following his resignation from such positions, Dr. Houston will remain on the Board as a director.
- Dr. Houston will also transition to a consultancy role, effective February 12, 2026, as discussed in greater detail below.
- On February 11, 2026, the Board appointed Briggs Morrison, M.D., currently the lead independent director of the Board, to be chair of the Board, effective as of the Effective Date.
- Dr. Teel, age 47, joined Arvinas in 2018 and has 20 years of biopharmaceutical industry experience.
- Dr. Teel has been the Company's Chief Business Officer since April 2024, and in that role was responsible for corporate strategy, business development, corporate communications, and investor relations.
- From February 2024 to June 2024, Dr. Teel also served as the Company's interim Chief Financial Officer, Treasurer and principal financial officer, while the Company undertook a search to identify the Company's next permanent Chief Financial Officer, Treasurer and principal financial officer.
- From September 2021 to April 2024, Dr. Teel served as the Company's Senior Vice President, Corporate and Business Development.
- From May 2018 to September 2021, Dr. Teel served as the Company's Vice President of Corporate Development.
Tools for this story
Each opens in a new tab, filled in for Arvinas, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
